First-Time-Right Drug Product Development for Small Molecules
At Crystal Pharmatech, we provide integrated formulation analytical development services for oral drug products, helping innovative biotech and pharmaceutical companies accelerate molecules from First-in-Human (FIH) studies to commercial manufacturing.
Unlike traditional “fit-for-purpose” strategies that often create costly downstream reformulation risks, our First-Time-Right philosophy ensures robust bioavailability, scalable manufacturing, and regulatory readiness from day one.
Oral Solid Dosage Forms
Most small molecule drugs are formulated as oral solid dosage (OSD) forms, such as tablets or capsules. OSD has been an important part of the global pharmaceutical market. The formulation team of Crys...
Amorphous Solid Dispersion (Spray Drying & Hot-melt Extrusion)
Recent statistics indicate that approximately 70% of small molecules under development belong to Biopharmaceutics Classification System (BCS) II or IV poorly water-soluble drugs. At Crystal Pharmatech...
Precision Dosing with 2 mm Mini-Tablet Technology
The development of acceptable, palatable pediatric formulations is undergoing transformation within the industry today, driven by patient needs and regulatory requirements. Therefore, the demand for a...
Why First-Time-Right Matters
Early shortcuts — such as powder-in-capsule or super placebo approaches — may slightly speed initial studies but frequently result in:
Reformulation after POC
Bioavailability variability
Additional human PK bridging studies with high cost
Regulatory delays
Our approach eliminates these risks through integrated design, predictive modeling, and scalable process with line of sight for late stage development.
The M3 Philosophy: Molecule · Material · Medicine
A well-designed analytical formulation must balance desired bioavailability, stability (physicochemical, and microbiological), and a scalable manufacturing process. We follow the M3 drug product development philosophy, creating tailor-made formulation designs for each molecule.
Molecule
We begin with a deep scientific understanding of your compound:
Target Product Profile (TPP) alignment
Early DMPK and pharmacodynamics assessment
Safety margin integration
Biopharmaceutics Classification System (BCS) positioning
Material
We analyze the physical and chemical foundation of the formulation:
Crystal form and solid-state properties
Crystallinity and polymorphism
Excipient compatibility and functionality
Mechanical and compaction behavior
Release and stability characteristics
Medicine
We design for the final patient experience and industrial scale drug product:
Label-driven formulation development strategy
CQA/CPP impact analysis
Risk-based QbD strategy
Regulatory-compliant scalability
Our Capability and Commitment
Crystal Pharmatech boasts a leadership team with deep expertise and state-of-the-art pilot plants. We strive to be your trusted partner, providing the technical and analytical data required for successful IND filings and beyond.
● Speed to FIH: Achieving "First-Time-Right with Line-of-Sight".
● Solubility Enhancement: Utilizing enabling technologies to improve bioavailability.
● Analytical Excellence: Developing and implementing validated analytical processes.
● Cost & Time Optimization: Streamlining the path forward with expert formulation recommendations.
Why Partner with Crystal Pharmatech?
● Scientific Expertise: A leadership team with an average of over 25 years of experience in multinational pharmaceutical companies.
● Proven Track Record: Successfully supported the development of over 100 innovative drugs, with 15 successfully commercialized.
● Top-of-the-Line Facilities: State-of-the-art pilot plants and labs equipped for R&D, advanced analysis, and manufacturing.
● Global Quality Standards: cGMP systems meeting NMPA, FDA, and EMA requirements, with 31 successful audits from global clients as of January 2026.
If you want to know more about cdmo services, please visit our website.
You must be logged in to post a comment.